Literature DB >> 12081824

Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease.

Harry R Gosker1, Mariëlle P K J Engelen, Henk van Mameren, Paul J van Dijk, Ger J van der Vusse, Emiel F M Wouters, Annemie M W J Schols.   

Abstract

BACKGROUND: Although the loss of peripheral muscle mass has been shown convincingly in chronic obstructive pulmonary disease (COPD), the underlying pathogenesis remains unclear.
OBJECTIVE: The aim of the present study was to determine the relations between skeletal muscle fiber types, fiber cross-sectional area (CSA), enzyme activities, and fat-free mass (FFM) in patients with COPD and in control subjects.
DESIGN: In 15 patients with COPD and 15 healthy, age-matched control subjects, FFM was determined by dual-energy X-ray absorptiometry and bioelectrical impedance analysis. In biopsy specimens from the vastus lateralis fiber types, fiber CSA and activities of cytochrome oxidase (EC 1.9.3.1), succinate dehydrogenase (EC 1.3.99.1), and glycogen phosphorylase (EC 2.4.1.1) were examined immunohistochemically and histochemically.
RESULTS: Compared with control subjects, patients with COPD had less FFM (49 compared with 59 kg, P = 0.030) and lower mean fiber CSA (3839 compared with 4647 microm(2), P = 0.037). A strong correlation (r = 0.87, P < 0.001) was observed between the FFM measured by bioelectrical impedance analysis and mean fiber CSA in patients with COPD. Within fiber-type categories the mean CSA of only the IIA/IIX and IIX fiber types was lower in patients than in control subjects [3358 compared with 4428 microm(2) (P = 0.022) and 2566 compared with 4248 microm(2) (P = 0.003), respectively]. In COPD, 20% of the type IIX fibers lacked stainable activities of cytochrome oxidase, succinate dehydrogenase, and glycogen phosphorylase, and this proportion correlated negatively with type IIX fiber CSA (r = -0.65, P = 0.012).
CONCLUSIONS: Muscle fiber atrophy occurs in the vastus lateralis in patients with COPD and contributes to the loss of muscle mass in COPD. Atrophy is specific to fiber types IIA/IIX and IIX and is associated with a disturbed metabolic capacity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12081824     DOI: 10.1093/ajcn/76.1.113

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  37 in total

Review 1.  Physiological and methodological considerations for the use of neuromuscular electrical stimulation.

Authors:  Nicola A Maffiuletti
Journal:  Eur J Appl Physiol       Date:  2010-05-15       Impact factor: 3.078

2.  Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases.

Authors:  Mp Swathi Karanth; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2017-04-01

3.  Peak anaerobic power in patients with COPD: gender related differences.

Authors:  R J Yquel; F Tessonneau; M Poirier; J Moinard; O Pillet; G Manier
Journal:  Eur J Appl Physiol       Date:  2006-04-22       Impact factor: 3.078

Review 4.  Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings.

Authors:  Joaquim Gea; Sergi Pascual; Carme Casadevall; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 5.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

6.  Cellular assessment of muscle in COPD: case studies of two males.

Authors:  Howard J Green; Eric Bombardier; Margaret E Burnett; Christine L D'Arsigny; Sobia Iqbal; Katherine A Webb; Jing Ouyang; Denis E O'Donnell
Journal:  Int J Gen Med       Date:  2009-12-29

Review 7.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

8.  Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease.

Authors:  W D-C Man; M G G Soliman; D Nikoletou; M L Harris; G F Rafferty; N Mustfa; M I Polkey; J Moxham
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

Review 9.  Reversal of chronic obstructive pulmonary disease-associated weight loss : are there pharmacological treatment options?

Authors:  Jean K Berry; Charles Baum
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Factors contributing to muscle wasting and dysfunction in COPD patients.

Authors:  Rob C I Wüst; Hans Degens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.